PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
London S.E.
11:35:01 2026-09-23 EDT
|
5-day change | 1st Jan Change | ||
| 116.00 GBX | +3.39% |
|
-2.85% | -7.20% |
| 09-09 | EARNINGS AND TRADING: Pebble Beach revenue grows as forecast | AN |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| Market Cap | 367M 322M 303M 277M 517M 35.16B 521M 3.64B 1.41B 17.92B 1.38B 1.35B 58.12B | P/E 2026 * |
-3.17x | P/E 2027 * | -3.22x |
|---|---|---|---|---|---|
| Enterprise Value | 93.54M 82.1M 77.18M 70.56M 132M 8.96B 133M 927M 359M 4.57B 351M 344M 14.81B | EV / Sales 2026 * |
11.9x | EV / Sales 2027 * | 10.1x |
| Free-Float |
84.36% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| PRTC | Delayed | |
CBOE
| PRTC | Real-time | |
|
Xetra
| 0VQ | End-of-day quote | |
|
OTC Markets
| PTCHF | Delayed | |
|
Deutsche Boerse AG
| 0VQ | Delayed | |
|
Börse Stuttgart
| 0VQ | Delayed |
Last Transcript: PureTech Health plc
| 1 day | +3.03% | ||
| 1 week | -2.85% | ||
| Current month | -7.94% | ||
| 1 month | -2.36% | ||
| 3 months | -12.12% | ||
| 6 months | +1.75% | ||
| Current year | -7.20% |
| 1 week | 110.4 |  | 127 |
| 1 month | 110.4 | | 129.2 |
| Current year | 107.4 | | 143.6 |
| 1 year | 107.4 | | 143.6 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 382.51 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 2025-07-14 |
Eric Elenko
PSD | President | 53 | 2024-04-08 |
Charles Sherwood
COO | Chief Operating Officer | - | 2021-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 2015-05-07 |
John LaMattina
BRD | Director/Board Member | 76 | 2008-12-31 |
| Director/Board Member | 73 | 2020-09-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/13/26 | Buy | Founder | 112,509 | 0.0466% | ||
| 9/24/25 | Buy | Chief Executive Officer | 81,051 | 0.0337% | ||
| 9/24/25 | Buy | Director | 29,239 | 0.0122% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.39% | -2.85% | -7.50% | -42.72% | 367M | |
| -0.18% | +4.35% | +4.23% | +30.02% | 47.86B | |
| -0.65% | -0.34% | +43.68% | +32.37% | 44.46B | |
| -1.33% | +4.19% | +10.21% | +90.50% | 41.85B | |
| -1.32% | -2.76% | +330.99% | +545.83% | 41.34B | |
| -0.62% | -0.06% | +10.15% | +46.02% | 30.04B | |
| -1.85% | +0.32% | +24.64% | +152.72% | 17.59B | |
| -5.56% | -10.23% | - | - | 15.6B | |
| -3.55% | +1.95% | +21.97% | +39.13% | 15.69B | |
| -0.89% | +8.93% | -9.41% | - | 13.93B | |
| Average | -1.30% | +1.76% | +47.66% | +111.73% | 26.87B | |
| Weighted average by Cap. | -1.32% | +1.87% | +67.97% | +141.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.85M 6.89M 6.48M 5.92M 11.06M 752M 11.15M 77.78M 30.15M 383M 29.48M 28.83M 1.24B | 14.01M 12.3M 11.56M 10.57M 19.75M 1.34B 19.9M 139M 53.84M 684M 52.62M 51.47M 2.22B |
| Net income | -135M -118M -111M -102M -190M -12.9B -191M -1.33B -517M -6.58B -506M -495M -21.32B | -119M -104M -98.22M -89.8M -168M -11.4B -169M -1.18B -457M -5.81B -447M -437M -18.85B |
| Net Debt | -273M -240M -226M -206M -385M -26.2B -388M -2.71B -1.05B -13.36B -1.03B -1B -43.3B | -226M -198M -186M -170M -319M -21.65B -321M -2.24B -868M -11.04B -849M -830M -35.78B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-23 | GBX 116.00 | +3.39% | 1,333,859 |
| 26-09-22 | GBX 112.20 | -7.27% | 2,309,004 |
| 26-09-21 | GBX 121.00 | -1.31% | 307,460 |
| 26-09-18 | GBX 122.60 | -0.81% | 766,496 |
| 26-09-17 | GBX 123.60 | +3.52% | 254,807 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
